| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e0eb3c391d7e38c89f330236184317fc |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate |
2009-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6aece18d2403eeccb461c653c3a12f9e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b2fa7cdc612cd7f68f305e57438267b |
| publicationDate |
2011-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20110110247-A |
| titleOfInvention |
Serum Markers Predicting Clinical Responses to Anti-NTFα Antibodies in Patients with Ankylosing Spondylitis |
| abstract |
The present invention provides a tool for managing a patient diagnosed with ankylosing spondylitis before initiation of therapy with an anti-TNFalpha formulation. The tool is an algorithm and specific marker for predicting response to therapy based on standard clinical primary and secondary endpoints using serum marker concentrations. In one embodiment, baseline levels of leptin or osteocalcin are used to predict response at week 14 after initiation of therapy. In another embodiment, the change in serum protein biomarker after the fourth week of therapy is used with complement component 3. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10393748-B2 |
| priorityDate |
2008-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |